1-Methyl-4-(2-nitrophenyl)piperazine, 97%
|
- $18.6 - $229
- Product name: 1-Methyl-4-(2-nitrophenyl)piperazine, 97%
- CAS: 62208-63-3
- MF: C11H15N3O2
- MW: 221.26
- EINECS:
- MDL Number:MFCD00156356
- Synonyms:Piperazine, 1-methyl-4-(2-nitrophenyl)-;1-Methyl-4-(2-nitrophenyl)piperazine,97%
4 prices
Selected condition：
Brand
- Alfa Aesar
- TRC
Package
- 250mg
- 1g
- 2.5g
- 5g
- ManufacturerAlfa Aesar
- Product numberH63368
- Product description1-Methyl-4-(2-nitrophenyl)piperazine, 97%
- Packaging250mg
- Price$18.6
- Updated2021-12-16
- Buy
- ManufacturerAlfa Aesar
- Product numberH63368
- Product description1-Methyl-4-(2-nitrophenyl)piperazine, 97%
- Packaging1g
- Price$53.2
- Updated2021-12-16
- Buy
- ManufacturerAlfa Aesar
- Product numberH63368
- Product description1-Methyl-4-(2-nitrophenyl)piperazine, 97%
- Packaging5g
- Price$229
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberM224663
- Product description1-Methyl-4-(2-nitrophenyl)piperazine
- Packaging2.5g
- Price$200
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Alfa Aesar | H63368 | 1-Methyl-4-(2-nitrophenyl)piperazine, 97% | 250mg | $18.6 | 2021-12-16 | Buy |
| Alfa Aesar | H63368 | 1-Methyl-4-(2-nitrophenyl)piperazine, 97% | 1g | $53.2 | 2021-12-16 | Buy |
| Alfa Aesar | H63368 | 1-Methyl-4-(2-nitrophenyl)piperazine, 97% | 5g | $229 | 2021-12-16 | Buy |
| TRC | M224663 | 1-Methyl-4-(2-nitrophenyl)piperazine | 2.5g | $200 | 2021-12-16 | Buy |
Properties
Boiling point :345.1±37.0 °C(Predicted)
Density :1.198±0.06 g/cm3(Predicted)
pka :7.50±0.42(Predicted)
form :Solid
Density :1.198±0.06 g/cm3(Predicted)
pka :7.50±0.42(Predicted)
form :Solid
Safety Information
| Symbol(GHS): |
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | |||||||||||||||||||||||||||||
| Hazard statements: |
|
||||||||||||||||||||||||||||
| Precautionary statements: |
|